— Know what they know.
Not Investment Advice

AREVF OTC

AREV Life Sciences Global Corp
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: -95.0% 3Y: -99.7% 5Y: -99.8%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Pharmaceuticals · Tech Score Neutral · Power 47 · $15881 mcap · 17M float · 0.055% daily turnover

Balance Sheet Trends

Total Assets
$253K -59.4% ▼
5Y CAGR: -31.4%
Total Liabilities
$1M +68.3% ▲
5Y CAGR: +11.5%
Shareholders Equity
-$953K -918.7% ▼
Cash & Investments
$94 -99.9% ▼
5Y CAGR: -84.5%
Total Debt
$29K -61.9% ▼
5Y CAGR: -36.7%
Net Debt
$29K +134.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$8K$30K$298K$158K$94
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$8K$30K$298K$158K$94
Net Receivables$0$3K$26K$129K$49K
Inventory$0$0$5K$20K$0
Other Current Assets$0$19K$515K$0$0
Total Current Assets$530K$86K$858K$338K$67K
Property, Plant & Equip.$0$794K$419K$284K$186K
Goodwill & Intangibles$2$0$0$0$0
Long-Term Investments$12K$12K$0$0$0
Other Non-Current Assets-$12K-$12K$0$0$0
Total Non-Current Assets$3$794K$419K$284K$186K
Total Assets$530K$879K$1M$623K$253K
— Liabilities —
Accounts Payable$179K$307K$433K$476K$805K
Short-Term Debt$428K$573K$636K$23K$29K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$45K$0$0-$36K$0
Total Current Liabilities$757K$1M$2M$716K$1M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$0$52K$0$0
Total Liabilities$757K$1M$2M$716K$1M
— Equity —
Common Stock$10M$11M$12M$13M$14M
Retained Earnings-$11M-$14M-$15M-$16M-$18M
Accumulated OCI$132$254$133$3M$101K
Total Stockholders Equity-$226K-$526K-$641K-$94K-$953K
Total Liabilities & Equity$530K$879K$1M$623K$253K
— Key Metrics —
Total Debt$428K$573K$736K$76K$29K
Net Debt$419K$544K$438K-$83K$29K
Total Investments$12K$12K$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms